Robert Hauser,
MD, MBA
Director, College Of Medicine Neurology
Professor, College Of Medicine Neurology
Education
- Fellowship, Movement Disorder, USF College of Medicine, 1990
- Residency, Neurosurgery, Eastern Virginia Grad. Med. School, 1988
- Internship, Surgery I, Albert Einstein Medical Center, 1983
- Medical School, Temple University School of Medicine, 1982
- MD, Temple University School of Medicine, 1982
Locations
-
Primary Address , 4001 E. Fletcher Avenue , 6th Floor Tampa, FL 33613
-
USF Academic Address , 5 Tampa General Cirlce , Suite 410 Tampa, FL 33606
-
Mail Point , STC 7th Floor ,
-
Physical Billing Address , 12901 Bruce B Downs BLVD Tampa, FL 33612
Clinical Interests
- parkinsons
- parkinson's
- parkinson
- movement disorders
Specialties
- Neurology-Parkinson's Disease AND Movement Disorders
Selected Publications
Shimberg, WR.Patel, NB.Sullivan, KL.Hauser, RA.Zesiewicz, TA.
Levetiracetam for stiff-person syndrome: report of 2 patients.
Clinical neuropharmacology. 31(5) : 301-2http://www.ncbi.nlm.nih.gov/pubmed/18836351
Simon, DK.Swearingen, CJ.Hauser, RA.Trugman, JM.Aminoff, MJ.Singer, C.Truong, D.Tilley, BC.
Caffeine and progression of Parkinson disease.
Clinical neuropharmacology. 31(4) : 189-96http://www.ncbi.nlm.nih.gov/pubmed/18670242
Lyons, KE.Friedman, JH.Hermanowicz, N.Isaacson, SH.Hauser, RA.Hersh, BP.Silver, DE.Tetrud, JW.Elmer, LW.Parashos, SA.Struck, LK.Lew, MF.Pahwa, R.
Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.
Clinical neuropharmacology. 33(1) : 5-10http://www.ncbi.nlm.nih.gov/pubmed/19855267
Zesiewicz, TA.Hauser, RA.Freeman, A.Sullivan, KL.Miller, AM.Halim, T.
Fentanyl-induced bradykinesia and rigidity after deep brain stimulation in a patient with Parkinson disease.
Clinical neuropharmacology. 32(1) : 48-50http://www.ncbi.nlm.nih.gov/pubmed/19471184
Hauser RA
Future treatments for Parkinson’s disease: surfing the PD pipeline
Int J Neurosci.. 2(121) : 53-62
Rascol O, Bronzova J, Hauser RA, Lang AE, Sampaio C, Theeuwes A, van de Witte SV
Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: Results of a double-blind, randomized, placebo-controlled, trial
Parkinsonism Relat Disord. , 2012.
Elm JJ; The NINDS NET-PD Investigators
Design innovations and baseline findings in a long-term Parkinson’s trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson’s Disease Long-Term Study-1
Mov Disord. 12(27) : 1513-1521, 2012.
Hauser RA, Lyons KE, Pahwa R
The UPDRS-8: A Brief Clinical Assessment Scale for Parkinson's Disease
Int J Neurosci. , 2012.
Hauser RA
IPX066: a novel carbidopa-levodopa extended-release formulation
Expert Rev Neurother. 2(12) : 133-40., 2012.
190. Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, Huyck S, Wolski K.
Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
Lancet Neurol. 3(10) : 221-9, 2011.
191. Hauser RA, Grosset DG
SPECT Brain Imaging in Patients With Suspected Parkinsonian Syndromes.
J Neuroimaging. , 2011.
Friedman JH, Agarwal P, Alcalay R, Black KJ, Chou KL, Cote L, Dayalu P, Frank S, Hartlein J, Hauser RA, Lang AE, Marsh L, Marshall F, Moskowitz C, Ravina B, Riley D, Sanchez-Ramos J, Simon DK, Simuni T, Sutton J, Tuite P, Weintraub D, Zesiewicz T
Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours.
Int J Neurosci.. 8(121) : 767-74, 2011.
192. Hauser RA, Auinger P, Parkinson Study Group
Determination of Minimal Clinically Important Change in Early and Advanced Parkinson's Disease.
Mov Disord. 5(26) : 813-8., 2011.
195. Gross RE, Watts RL, Hauser RA, Bakay RA, Reichmann H, von Kummer R, Ondo WG, Reissig E, Eisner W, Steiner-Schulze H, Siedentop H, Fichte K, Hong W, Cornfeldt M, Beebe K, Sandbrink R; the Spheramine Investigational Group.
Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial.
Lancet Neurol. 6(10) : 509-519., 2011.
Poewe W, Rascol O, Barone P, Hauser RA, Mizuno Y, Haaksma M, Salin L, Juhel N, Schapira AH
Pramipexole ER Studies Group. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial
Neurology. 8(77) : 759-66, 2011.
196. Rascol, O., Fitzer-Attas, C.J., Hauser, R., Jankovic, J., Lang, A., Langston, J. W., …AND Olanow, C. W.
A double-blind, delayed-start trial of rasgiline in Parkinson’s disease (the ADAGIO study) : prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
The Lancet Neurology. 5(10) : 415-423, 2011.
Hauser RA, Ellenbogen AL, Metman LV, Hsu A, O'Connell MJ, Modi NB, Yao HM, Kell SH, Gupta SK
Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease
Mov Disord. 12(26) : 2246-52, 2011.
193. Hauser RA, Reichmann H, Lew M, Asgharian A, Makumi C, Shulman KJ
Long-term, Open-label Study of Once-daily Ropinirole Prolonged Release in Early Parkinson's Disease.
Int J Neurosci. 5(121) : 246-53, 2011.
195. Gross RE, Watts RL, Hauser RA, Bakay RA, Reichmann H, von Kummer R, Ondo WG, Reissig E, Eisner W, Steiner-Schulze H, Siedentop H, Fichte K, Hong W, Cornfeldt M, Beebe K, Sandbrink R; the Spheramine Investigational Group
Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial
Lancet Neurol. 6(10) : 509-519, 2011.
194. Sampaio C, Bronzova J, Hauser RA, Lang AE, Rascol O, van de Witte SV, Theeuwes AA; for the Rembrandt/Vermeer Study Groups
Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double-blind trials.
Mov Disord. 8(26) : 1464-76, 2011.
Bronzova, J.Sampaio, C.Hauser, RA.Lang, AE.Rascol, O.Theeuwes, A.van de Witte, SV.van Scharrenburg, G.
Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society. 25(6) : 730-8, 2010.
http://www.ncbi.nlm.nih.gov/pubmed/20198713
Colosimo, C.Martínez-Martín, P.Fabbrini, G.Hauser, RA.Merello, M.Miyasaki, J.Poewe, W.Sampaio, C.Rascol, O.Stebbins, GT.Schrag, A.Goetz, CG.
Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations.
Movement disorders : official journal of the Movement Disorder Society. 25(9) : 1131-42, 2010.
http://www.ncbi.nlm.nih.gov/pubmed/20310033
Hauser, RA.
Early pharmacologic treatment in Parkinson's disease.
The American journal of managed care. 16 Suppl Implications: S100-7, 2010.
http://www.ncbi.nlm.nih.gov/pubmed/20297870
Watts, RL.Lyons, KE.Pahwa, R.Sethi, K.Stern, M.Hauser, RA.Olanow, W.Gray, AM.Adams, B.Earl, NL.
Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society. 25(7) : 858-66, 2010.
http://www.ncbi.nlm.nih.gov/pubmed/20461803
Lew, MF.Hauser, RA.Hurtig, HI.Ondo, WG.Wojcieszek, J.Goren, T.Fitzer-Attas, CJ.
Long-term efficacy of rasagiline in early Parkinson's disease.
The International journal of neuroscience. 120(6) : 404-8, 2010.
http://www.ncbi.nlm.nih.gov/pubmed/20504210
Hersh, BP.Earl, NL.Hauser, RA.Stacy, M.
Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations.
Movement disorders : official journal of the Movement Disorder Society. 25(7) : 927-31, 2010.
http://www.ncbi.nlm.nih.gov/pubmed/20461810
Rascol, O.Barone, P.Hauser, RA.Mizuno, Y.Poewe, W.Schapira, AH.Salin, L.Sohr, M.Debieuvre, C.
Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society. 25(14) : 2326-32, 2010.
http://www.ncbi.nlm.nih.gov/pubmed/20669265
189. Butterfield LC, Cimino CR, Oelke LE, Hauser RA, Sanchez-Ramos J
The independent influence of apathy and depression on cognitive functioning in Parkinson's disease.
Neuropsychology. 6(24) : 721-30, 2010.
Hauser, RA.Schapira, AH.Rascol, O.Barone, P.Mizuno, Y.Salin, L.Haaksma, M.Juhel, N.Poewe, W.
Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society. 25(15) : 2542-9, 2010.
http://www.ncbi.nlm.nih.gov/pubmed/20669317
Connors, JJ.Sacks, D.Furlan, AJ.Selman, WR.Russell, EJ.Stieg, PE.Hadley, MN.Wojak, JC.Koroshetz, WJ.Heros, RC.Strother, CM.Duckwiler, GR.Durham, JD.Tom-sick, TO.Rosenwasser, RH.McDougall, CG.Haughton, VM.Derdeyn, CP.Wechsler, LR.Hudgins, PA.Alberts, MJ.Raabe, RD.Gomez, CR.Cawley, CM.Krol, KL.Futrell, N.Hauser, RA.Frank, JI.
Training, competency, and credentialing standards for diagnostic cervicocerebral angiography, carotid stenting, and cerebrovascular intervention: a joint statement from the American Academy of Neurology, the American Association of Neurological Surgeons, the American Society of Interventional and Therapeutic Neuroradiology, the American Society of Neuroradiology, the Congress of Neurological Surgeons, the AANS/CNS Cerebrovascular Section, and the Society of Interventional Radiology.
Journal of vascular and interventional radiology : JVIR. 20(7 Suppl) : S292-301, 2009.
http://www.ncbi.nlm.nih.gov/pubmed/19560013
Tanner, CM.Ross, GW.Jewell, SA.Hauser, RA.Jankovic, J.Factor, SA.Bressman, S.Deligtisch, A.Marras, C.Lyons, KE.Bhudhikanok, GS.Roucoux, DF.Meng, C.Abbott, RD.Langston, JW.
Occupation and risk of parkinsonism: a multicenter case-control study.
Archives of neurology. 66(9) : 1106-13, 2009.
http://www.ncbi.nlm.nih.gov/pubmed/19752299
Hauser, RA.Auinger, P.Oakes, D.
Levodopa response in early Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society. 24(16) : 2328-36, 2009.
http://www.ncbi.nlm.nih.gov/pubmed/19908302
Hauser, RA.Lyons, KE.McClain, T.Carter, S.Perlmutter, D.
Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society. 24(7) : 979-83, 2009.
http://www.ncbi.nlm.nih.gov/pubmed/19230029
Seeberger, LC.Hauser, RA.
Levodopa/carbidopa/entacapone in Parkinson's disease.
Expert review of neurotherapeutics. 9(7) : 929-40, 2009.
http://www.ncbi.nlm.nih.gov/pubmed/19589043
Jahan, I.Hauser, RA.Sullivan, KL.Miller, A.Zesiewicz, TA.
Sleep disorders in Parkinson's disease.
Neuropsychiatric disease and treatment. 5: 535-40, 2009.
http://www.ncbi.nlm.nih.gov/pubmed/19898667
Hauser, RA.
Levodopa: past, present, and future.
European neurology. 62(1) : 1-8, 2009.
http://www.ncbi.nlm.nih.gov/pubmed/19407449
Hauser, RA.Lew, MF.Hurtig, HI.Ondo, WG.Wojcieszek, J.Fitzer-Attas, CJ.
Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society. 24(4) : 564-73, 2009.
http://www.ncbi.nlm.nih.gov/pubmed/19086083
Simuni, T.Lyons, KE.Pahwa, R.Hauser, RA.Comella, C.Elmer, L.Weintraub, D.
Treatment of early Parkinson's disease. Part 1.
European neurology. 61(4) : 193-205, 2009.
http://www.ncbi.nlm.nih.gov/pubmed/19176960
Simuni, T.Lyons, KE.Pahwa, R.Hauser, RA.Comella, C.Elmer, L.Weintraub, D.
Treatment of early Parkinson's disease. Part 2.
European neurology. 61(4) : 206-15, 2009.
http://www.ncbi.nlm.nih.gov/pubmed/19176961
Sethi, KD.Hauser, RA.Isaacson, SH.McClain, T.
Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo 200) in the treatment of Parkinson's disease: a case series.
Cases journal. 2: 7134, 2009.
http://www.ncbi.nlm.nih.gov/pubmed/19829918
Olanow, CW.Hauser, RA.Jankovic, J.Langston, W.Lang, A.Poewe, W.Tolosa, E.Stocchi, F.Melamed, E.Eyal, E.Rascol, O.
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.
Movement disorders : official journal of the Movement Disorder Society. 23(15) : 2194-201, 2008.
http://www.ncbi.nlm.nih.gov/pubmed/18932271
Goetz, CG.Wuu, J.McDermott, MP.Adler, CH.Fahn, S.Freed, CR.Hauser, RA.Olanow, WC.Shoulson, I.Tandon, PK.Leurgans, S.
Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions.
Movement disorders : official journal of the Movement Disorder Society. 23(5) : 690-9, 2008.
http://www.ncbi.nlm.nih.gov/pubmed/18228568
Zesiewicz, TA.Sullivan, KL.Hoffmann, M.Benes, LM.Smith, DA.Ward, CL.Hauser, RA.
Delayed thalamic intracranial hemorrhage in an essential tremor patient following deep brain stimulation.
European neurology. 59(3-4) : 187-9, 2008.
http://www.ncbi.nlm.nih.gov/pubmed/18230878
Kordower, JH.Chu, Y.Hauser, RA.Freeman, TB.Olanow, CW.
Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease.
Nature medicine. 14(5) : 504-6, 2008.
http://www.ncbi.nlm.nih.gov/pubmed/18391962
Encarnacion, EV.Hauser, RA.
Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
European neurology. 60(2) : 57-66, 2008.
http://www.ncbi.nlm.nih.gov/pubmed/18480609
Kordower, JH.Chu, Y.Hauser, RA.Olanow, CW.Freeman, TB.
Transplanted dopaminergic neurons develop PD pathologic changes: a second case report.
Movement disorders : official journal of the Movement Disorder Society. 23(16) : 2303-6, 2008.
http://www.ncbi.nlm.nih.gov/pubmed/19006193
Hauser, RA.Shulman, LM.Trugman, JM.Roberts, JW.Mori, A.Ballerini, R.Sussman, NM.
Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
Movement disorders : official journal of the Movement Disorder Society. 23(15) : 2177-85, 2008.
http://www.ncbi.nlm.nih.gov/pubmed/18831530